Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Pharmacokinetics of MDV3100 1Neoplasm Metastasis 1Meningioma 1Memory Disorders 1Glioblastoma 1Cognitive Dysfunction 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 107Radiotherapy 60Radiation 28Bevacizumab 19Magnetic Resonance Spectroscopy 16Nivolumab 15Surgical Procedures, Operative 12Irinotecan 11Cyclophosphamide 10Specimen Handling 9Chemotherapy, Adjuvant 9Radiotherapy, Intensity-Modulated 8Radiosurgery 8O(6)-benzylguanine 8Carmustine 8poly ICLC 7pembrolizumab 7motexafin gadolinium 7fludarabine 7Leukapheresis 7Flucytosine 7sargramostim 6Radiotherapy, Conformal 6Erlotinib Hydrochloride 6Lomustine 5Ipilimumab 5Imiquimod 5Imatinib Mesylate 5Hydroxyurea 5Granulocyte-Macrophage Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Glioblastoma × Pioglitazone × Clear all
NCT01151670 2018-08-01

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Wake Forest University Health Sciences

Phase 1 Completed
18 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Memory Disorders, Meningioma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡